Volume 10, Issue 3 (9-2022)                   JoMMID 2022, 10(3): 104-113 | Back to browse issues page


XML Print


Department of Microbiology, Government Medical College, Srinagar, India
Abstract:   (1041 Views)
Introduction: The increased frequency of Methicillin-resistant Staphylococcus aureus infections has led to renewed interest in the macrolide-lincosamide streptogramin B (MLS) group of antibiotics. Resistance to these antibiotics may be constitutive or inducible. Isolates resistant to erythromycin may show false in vitro susceptibility to clindamycin, leading to therapeutic failures. This study investigated the utility of the D-Test for detecting inducible clindamycin resistance in methicillin-resistant S. aureus isolates and determining the prevalence of various phenotypes in our region. Methods: For detecting inducible clindamycin resistance, a D-test using erythromycin and clindamycin as per CLSI guidelines was performed, and four different phenotypes were interpreted as methicillin-sensitive (MS) phenotype (D-test negative), inducible MLSB (iMLSB) phenotype (D-test positive), constitutive MLSB phenotype and sensitive to both. Results: Of the 987 isolates tested, 400 (40.53%) were MRSA. The prevalence of iMLSB, cMLSB phenotype, MS phenotype and sensitive phenotype in MRSA isolates was 42.5%, 10.5%, 28% and 19%, respectively. The iMLSB and cMLSB phenotypes were higher in males (24.75%, 6.25%) than females (P-value = 0.137). The majority of MRSA isolates originated from pus (83%). All S. aureus isolates showed 100% sensitivity to vancomycin and linezolid.  Conclusion: This study emphasizes the prevalence of inducible clindamycin resistance in MRSA in our setup. Incorporating the D-test into the routine Kirby–Bauer disk diffusion method in clinical microbiology laboratories will help clinicians make judicious use of clindamycin, minimizing treatment failure.
Full-Text [PDF 1107 kb]   (526 Downloads)    
Type of Study: Original article | Subject: Anti-microbial agents, resistance and treatment protocols
Received: 2022/02/9 | Accepted: 2022/09/19 | Published: 2022/10/12

References
1. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008; 46 (suppl 5): S350-9. [DOI:10.1086/533591]
2. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol. 2008; 8 (6): 747-63. [DOI:10.1016/j.meegid.2008.07.007]
3. Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol.1998; 6 (12): 484-8. [DOI:10.1016/S0966-842X(98)01400-0]
4. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community associated Methicillin resistant Staphylococcus aureus. Lancet. 2010; 375: 1557-68. [DOI:10.1016/S0140-6736(09)61999-1]
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control. 2003; 31 (8): 481-98. [DOI:10.1016/j.ajic.2003.09.002]
6. David MZ, Daum RS. Community associated Methicillin resistant Staphylococcus aureus: Epidemiology and consequences of an emerging epidemic. Clin Microbiol Rev. 2010; 23 (3): 616-87. [DOI:10.1128/CMR.00081-09]
7. Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010; 15 (41): 19688. [DOI:10.2807/ese.15.41.19688-en]
8. Patel AK, Patel KK, Patel KR, Shah S, Dileep P. Time trends in the epidemiology of microbial infections at a tertiary care center in west India over last 5 years. J Assoc Physicians India. 2010; 58 Suppl: 37-40.
9. Gopalakrishnan R, Sureshkumar D. Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8-year period in a tertiary care hospital in relation to introduction of an infection control programme. J Assoc Physicians India. 2010; 58 Suppl: 25-31.
10. D'Souza N, Rodrigues C, Mehta A. Molecular characterization of Methicillin-resistant Staphylococcus aureus with emergence of epidemic clones of sequence type (ST) 22 and ST 772 in Mumbai, India. J Clin Microbiol. 2010; 48 (5): 1806-11. [DOI:10.1128/JCM.01867-09]
11. Ahmad S. Prevalence and susceptibility pattern of Methicillin Resistant Staphylococcus aureus (MRSA) in Kashmir. Bangladesh J Medical Sci. 2013; 12 (4). [DOI:10.3329/bjms.v12i4.16663]
12. Rajaduraipandi K, Mani KR, Panneerselvam KM, Bhaskar M, Manikandan P. Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus: a multicentre study. Indian J Med Microbiol. 2006; 24 (1): 34-8. [DOI:10.1016/S0255-0857(21)02468-3]
13. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus. J Clin Microbial. 2003; 41 (10): 4740-4. [DOI:10.1128/JCM.41.10.4740-4744.2003]
14. Dass BS, Nagarajan A, Krishnan P, Sivakumar G. clindamycin resistance among Staphylococcus aureus causing skin and ear infections from Chennai, South India. BMC Infect Dis. 2012; 12 (Suppl 1): 70. [DOI:10.1186/1471-2334-12-S1-P70]
15. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R. Inducible clindamycin resistance in clinical isolates of Staphylococcus aureus. Indian J Med Res. 2006; 123 (4): 571-3.
16. Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection and prevalence of inducible clindamycin resistance in Staphylococci. J Med Microbiol. 2007; 56 (Pt 3): 342-5. [DOI:10.1099/jmm.0.46761-0]
17. Azap O, Arslan H, Timurkaynak F, Yapar G, Oruc E, Gagir U. Incidence of inducible clindamycin resistance in Staphylococci: first results from Turkey. Clin Microbiol Infect. 2005; 11 (7): 582-4. [DOI:10.1111/j.1469-0691.2005.01174.x]
18. Introduction to microbiology: Part II: Guidelines for collection, transport, processing, analysis and reporting of cultures from specific specimen sources. In: Winn WC, Allen SD, Janda WM, Koneman EW, Procop GW, Woods GL as editors: Colour Atlas and textbook of medical microbiology. 6th edition. Lippincott Williams and Wilkins Philadelphia: 2006: 111-31.
19. Clinical and laboratory standard institute. Performance standards for antimicrobial susceptibility testing; 27th informational supplement. (M100-S26). Wayne: CLSI (2017).
20. Shetty J, Afroz Z. Prevalence of constitutive and inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care institute in North India. Int J Res Med Sci. 2017; 5 (7): 3120-5. [DOI:10.18203/2320-6012.ijrms20172999]
21. Singh T, Deshmukh AB, Chitnis V, Bajpai T. Inducible clindamycin resistance among the clinical isolates of Staphylococcus aureus in a tertiary care hospital. Int J Health Allied Sci. 2016; 5 (2): 111-4. [DOI:10.4103/2278-344X.180428]
22. Reddy MC, Bindu HM, Soumendranath M, Kanta RC, Kapur I. Prevalence of inducible Clindamycin resistance in Staphylococcus aureus from clinical samples: A study from a teaching hospital in Andhra Pradesh, India. Int J Curr Microbiol App Sci. 2014; 3 (3): 402-9.
23. Patil NR, Mali US, Kulkarni SA, Ghorpade MV and Mane V. Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care hospital. Int J Curr Microbiol App Sci. 2014; 3 (9): 689-94.
24. Damke SS, Vishani S, Fule RP. Prevalence of inducible clindamycin resistance of staphylococcus aureus in hospitalized patients in tertiary care hospital. Int J Cur Res Rev. 2017; 9 (8): 14-7.
25. Tyagi S, Oberoi A. Inducible clindamycin resistance in staphylococcus aureus isolates and its correlation with multidrug resistance: a study from north India. J Evolution Med Dent Sci. 2016; 5 (16): 749-52. [DOI:10.14260/jemds/2016/173]
26. Majhi S, Dash M, Mohapatra D, Mohapatra A, Chayani N. Detection of inducible and constitutive clindamycin resistance among Staphylococcus aureus isolates in a tertiary care hospital, Eastern India. Avicenna J Med. 2016; 6 (3): 75-80. [DOI:10.4103/2231-0770.184066]
27. Banik A, Khyriem AB, Gurung J, Lyngdoh VW. Inducible and constitutive clindamycin resistance in Staphylococcus aureus in a north-eastern Indian tertiary care hospital. J Infect Dev Ctries. 2015; 9 (7): 725-31. [DOI:10.3855/jidc.6336]
28. Mama M, Aklilu A, Misgna K, Tadesse M, Alemayehu E. Methicillin- and Inducible Clindamycin-Resistant Staphylococcus aureus among Patients with Wound Infection Attending Arba Minch Hospital, South Ethiopia. Int J Microbiol. 2019: 2965490. [DOI:10.1155/2019/2965490]
29. Jarajreh D, Aqel A, Alzoubi H, Al-Zereini W. Prevalence of inducible clindamycin resistance in methicillin-resistant Staphylococcus aureus: the first study in Jordan. J Infect Dev Ctries. 2017; 11 (4): 350-4. [DOI:10.3855/jidc.8316]
30. Sasirekha B, Usha MS, Amruta JA, Ankit S, Brinda N, Divya R. Incidence of constitutive and inducible clindamycin resistance among hospital-associated Staphylococcus aureus. 3 Biotech. 2014; 4 (1): 85-9. [DOI:10.1007/s13205-013-0133-5]
31. Appalaraju B, Jayakumar S. Inducible Clindamycin Resistance in Staphylococcus aureus isolated from clinical samples. J Commun Dis. 2010; 42 (4): 263-8.
32. Mittal V, Kishore S, Siddique ME. Prevalence of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus detected by phenotypic method: A preliminary report. J Infect Dis Immun. 2013; 5 (1): 10-2. [DOI:10.5897/JIDI12.005]
33. Pal N, Sharma B, Sharma R, Vyas L. Detection of inducible clindamycin resistance among staphylococcal isolates from different clinical specimens in Western India. J Postgrad Med. 2010; 56 (3): 182-5. [DOI:10.4103/0022-3859.68637]
34. Shrestha B, Pokhrel BM, Mohapatra TM. Phenotypic characterization of nosocomial isolates of Staphylococcus aureus with reference to MRSA. J Infect Dev Ctries. 2009; 3 (7): 554-60. [DOI:10.3855/jidc.474]
35. Mokta KK, Verma S, Chauhan D, Ganju SA, Singh D, Kanga A, et al. Inducible clindamycin resistance among clinical isolates of Staphylococcus aureus from sub Himalayan Region of India. J Clin Diagn Res. 2015; 9 (8): DC20‑3. [DOI:10.7860/JCDR/2015/13846.6382]
36. Chudasama V, Solanki H, Vadsmiya M, Vegad MM. Prevalence of inducible clindamycin resistance of Staphylococcus aureus from various clinical specimens by D test in tertiary care hospital. IOSR J Dent Med Sci. 2014; 13 (3): 29‑32. [DOI:10.9790/0853-13312932]
37. Supriyarajvi, Gupta A, Tina G, Sharma BP. Detection of inducible Clindamycin Resistance among Staphylococcal isolates from various clinical specimens in a tertiary care institute in North west region of Rajasthan, India. Int J Curr Microbiol App Sci. 2015; 4 (10): 741-9.
38. Koppada R, Meeniga S, Anke G. Inducible clindamycin resistance among in Staphylococcus aureus isolated from various clinical samples with special reference to MRSA. Sch J Appl Med Sci. 2015; 3: 2374‑80.
39. Sande (Tathe) SV. Phenotypic detection and incidence of inducible clindamycin resistance among Staphylococcus aureus from tertiary care hospital. Int J Adv Med. 2015; 2 (3): 264-8. [DOI:10.18203/2349-3933.ijam20150557]
40. Lall M, Sahni AK. Prevalence of inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples. Med J Armed Forces India. 2014; 70 (1): 43-7. [DOI:10.1016/j.mjafi.2013.01.004]
41. Lyall KS, Veenu Gupta, and Deepinder Chhina. Inducible clindamycin resistance among clinical isolates of Staphylococcus aureus. J Mahatma Gandhi Inst Med Sci. 2013; 18 (2): 112-5. [DOI:10.4103/0971-9903.117799]
42. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of Constitutive and Inducible Clindamycin Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci in a Community and a Tertiary Care Hospital. J Clin Microbiol. 2004; 42 (6): 2777-9. [DOI:10.1128/JCM.42.6.2777-2779.2004]
43. Date K, Choudhary M, Thombare V. Inducible clindamycin resistance in clinical isolates of staphylococci in a rural hospital. Int J Biol Med Res. 2012; 3: 1922-5.
44. Santos Sanchez I, Mato R, de Lencastre H, Tomasz A; CEM/NET Collaborators and International Collaborators. Patterns of multi-drug resistance among methicillin-resistant hospital isolates of coagulase positive and coagulase negative Staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist. 2000; 6 (3): 199-211. [DOI:10.1089/mdr.2000.6.199]
45. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R et al. Methicillin-Resistant Staphylococcus aureus (MRSA): Prevalence and Antimicrobial Sensitivity Pattern among Patients-A Multicenter Study in Asmara, Eritrea. Can J Infect Dis Med Microbiol. 2019; 8321834. [DOI:10.1155/2019/8321834]
46. Ghosh S, Banerjee M. Methicillin resistance & inducible clindamycin resistance in Staphylococcus aureus. Indian J Med Res. 2016; 143 (3): 362-4. [DOI:10.4103/0971-5916.182628]
47. Motamedifar M, Ebrahim-Saraie HS, Mansury D. Patterns of Constitutive and Inducible Clindamycin Resistance in Staphylococcus aureus Isolated from Clinical Samples by D-test Method, Shiraz, Southwest of Iran. Galen Medical Journal. 2014; 3 (4): 216-8. [DOI:10.31661/gmj.v3i4.204]
48. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin resistant Staphylococcus aurous infections among patients in the emergency department. N Engl J Med. 2006; 355 (7): 666-74. [DOI:10.1056/NEJMoa055356]
49. Nikbakht M, Rezaee MA, Hasani A, Nahaei MA, Sadeghi J, Seifi SJ. Phenotypic and Genotypic Study of Inducible Clindamycin Resistance in Clinical Isolates of Staphylococcus aureus in Tabriz, Northwest Iran. Jundishapur J Microbiol. 2017; 10 (1): 1-8. [DOI:10.5812/jjm.39274]
50. Fomda BA, Ahmad PM, Zahoor D, Thokar MA, Nasir RA. Phenotypic detection of constitutive and inducible clindamycin resistance in clinical isolates of Staphylococcus aureus and coagulase negative Staphylococcus on routine susceptibility plate. J Commun Dis. 2010; 42 (1): 19-26.
51. Anouk E Muller, JW Mouton, PM Oostvogel, PJ Rob, AV, Joost D, Eric AP, et al. Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period. Antimicrob Agents Chemother. 2010; 54 (5): 2175-81. [DOI:10.1128/AAC.01017-09]
52. Martinez AG, Hammermann WA, Manson EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community acquired Methicillin resistant and methicillin susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003; 22 (7): 593-8. [DOI:10.1097/01.inf.0000073163.37519.ee]
53. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc. 1999; 74 (8): 825-33. [DOI:10.4065/74.8.825]
54. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev. 2002; 15 (3): 430-8. [DOI:10.1128/CMR.15.3.430-438.2002]
55. Johnson AP, Woodford N. Glycopeptide-resistant Staphylococcus aureus. J Atimicrob Chemother. 2002; 50 (5): 621-3. [DOI:10.1093/jac/dkf244]
56. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Cli Infect Dis. 2003; 36 (4): 473-81. [DOI:10.1086/367662]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.